Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

Insulin resistance in polycystic ovary syndrome phenotypes and the vicious cycle model in its etiology

Szkodziak P., Szkodziak F., Trzeciak K., Woźniak S., Mlynarczyk M., Paszkowski T.

Retrospective Study on Type 2 Diabetes, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Sci Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41315368
PMCID
PMC12663220
DOI
10.1038/s41598-025-26718-2
Citations
1

Abstract (original English)

Polycystic ovary syndrome (PCOS) is a multifactorial disorder driven by at least three pathophysiological components: hypothalamic, ovarian, and obesity-related mechanisms. Insulin resistance (IR) is a unifying feature. Reciprocal interactions among androgen excess, hyperinsulinemia, and reduced hepatic sex hormone-binding globulin production create a self‑sustaining "vicious cycle" that exacerbates PCOS manifestations, which vary in severity and define four clinical phenotypes. To evaluate insulin resistance across PCOS phenotypes A (HA + OD + PCOM), B (HA + OD), C (HA + PCOM), and D (OD + PCOM). A retrospective observational study (2018-2022) of 200 Caucasian women aged 18-36 diagnosed with PCOS according to the Rotterdam criteria. Insulin resistance was assessed using HOMA‑IR. Clinical and anthropometric variables, Free Androgen Index (FAI), and Ferriman‑Gallwey (mFG) scores were analyzed by phenotype. Insulin resistance was present in 57.5% of participants. HOMA‑IR showed no correlation with PCOS duration but differed significantly between phenotypes. Mean HOMA‑IR values exceeded reference thresholds in all phenotypes: A 3.59, B 2.59, C 2.05, D 2.73. Moderate to strong positive correlations were observed between HOMA‑IR and mean arterial pressure, pulse rate, and waist‑to‑hip ratio, indicating an association with cardiometabolic risk across phenotypes. Positive associations

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansPolycystic Ovary SyndromeInsulin ResistanceSex Hormone-Binding GlobulinRetrospective StudiesPhenotypeAdolescentAdultFemaleYoung Adult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research